Compare ARMOUR Residential REIT, Inc. (ARR) vs IDEXX Laboratories, Inc. (IDXX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ARMOUR Residential REIT, Inc. vs IDEXX Laboratories, Inc. — how do they compare? ARMOUR Residential REIT, Inc. trades at $16.73 (market cap $2.07B), while IDEXX Laboratories, Inc. trades at $571.56 (market cap $46.22B). The key difference: IDEXX Laboratories, Inc. is far larger — about 22.3× ARMOUR Residential REIT, Inc.'s market cap, and ARMOUR Residential REIT, Inc. pays a 17.28% dividend while IDEXX Laboratories, Inc. pays none. Which is the better fit depends on your goals.
| ARR | IDXX | |
|---|---|---|
Market Cap | $2.07B | $46.22B |
Sector | Financials | Health |
52-Week High | $19.12 | $766.68 |
52-Week Low | $14.05 | $526.44 |
Dividend Yield | 17.28% | — |
Enterprise Value | — | $47.12B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ARMOUR Residential REIT (ARR) trades at $16.54, down 0.84% on the day, amid a bearish technical signal. The stock shows a low P/E of 3.78 and trades below book value (P/B 0.91), suggesting potential undervaluation. Recent earnings were mixed, with a Q2 2026 beat but a Q4 2025 miss. The company maintains a high net income margin of 97.43% and consistent dividend payments, with the latest being $0.24 per share. Cash flow from operations improved to $319 million in 2026, though investing outflows remain high.
ARR presents a value opportunity with strong profitability and dividends, but faces risks from volatile earnings, high investing cash outflows, and a bearish technical outlook. Analyst sentiment is mixed, with 60% hold ratings. The stock's appeal hinges on sustained dividend payments and earnings stability amid interest rate sensitivity.
IDEXX Laboratories (IDXX) trades at $595.76, up 1.55% on the day, with a bullish technical signal and strong fundamental performance. Recent Q2 2026 earnings beat expectations with EPS of $4.27 versus $3.94 expected, driven by 9% organic revenue growth. The company raised full-year EPS guidance to $14.69–14.94, reflecting robust demand in companion animal diagnostics. Valuation ratios remain elevated with a P/E of 41.23, supported by high profitability margins including a net income margin of 25.03% and ROE of 74.21%.
Outlook is positive given consistent earnings beats, international expansion, and product innovation, but risks include premium valuation sensitivity and competitive pressures. The consensus price target of $683.33 implies 14.7% upside, with 57% of analysts rating it Buy. Investors should weigh growth durability against high multiples.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ARMOUR Residential REIT, Inc.
ARMOUR Residential REIT Inc is a real estate investment trust that invests in residential mortgage-backed securities or RMBS. These are issued or guaranteed by U.S.-government-sponsored enterprises, such as Fannie Mae, Freddie Mac, or Ginnie Mae. The company's investment portfolio is composed of mortgage-backed securities, adjustable-rate mortgage securities, and multifamily mortgage-backed securities. In terms of total fair value, most Armour's investments are long-term, fixed-rate agency RMBS. Multifamily RMBS also represents a substantial amount. Fannie Mae guarantees most of the company's holdings. Armour derives substantially all its revenue as interest income from its investments.
Read more on ARR →About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →
